Neptune Enters Pharmaceutical Market
Neptune Technology and Bioressources Inc. (Neptune; Laval, QC), a supplier of krill oil for dietary supplements, has introduced Onemia, a medical food for the pharmaceutical market.
Neptune Technology and Bioressources Inc. (Neptune; Laval, QC), a supplier of krill oil for dietary supplements, has introduced Onemia, a medical food for the pharmaceutical market.
Onemia is a marine-based omega-3 phospholipid deemed by FDA as safe and effective for managing chronic cardiometabolic disorders. Available through prescription, the product can be used alone or in combination with other cardiovascular drugs.
"The success of Onemia will provide short-term revenues which will contribute to Acasti's further research and development projects while establishing a validation of Acasti's omega-3 phospholipid pipeline…paving the road for CaPre, our prescription drug candidate in development," said Tina Sampalis, MD, PhD, president of Neptune.
Onemia is manufactured by Neptune and sold through the company’s subsidiary, Acasti Pharma Inc.
